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Abstract
Background: Activation of peroxisome proliferator-activated receptor (PPAR)gamma is associated with bone loss
and increased fracture risk, while PPARalpha activation seems to have positive skeletal effects. To further explore
these effects we have examined the effect of the PPARalpha agonists fenofibrate and Wyeth 14643, and the
PPARgamma agonist pioglitazone, on bone mineral density (BMD), bone architecture and biomechanical strength
in ovariectomized rats.
Methods: Fifty-five female Sprague-Dawley rats were assigned to five groups. One group was sham-operated and
given vehicle (methylcellulose), the other groups were ovariectomized and given vehicle, fenofibrate, Wyeth 14643
and pioglitazone, respectively, daily for four months. Whole body and femoral BMD were measured by dual X-ray
absorptiometry (DXA), and biomechanical testing of femurs, and micro-computed tomography (microCT) of the
femoral shaft and head, were performed.
Results: Whole body and femoral BMD were significantly higher in sham controls and ovariectomized animals given
fenofibrate, compared to ovariectomized controls. Ovariectomized rats given Wyeth 14643, maintained whole body
BMD at sham levels, while rats on pioglitazone had lower whole body and femoral BMD, impaired bone quality and
less mechanical strength compared to sham and ovariectomized controls. In contrast, cortical volume, trabecular
bone volume and thickness, and endocortical volume were maintained at sham levels in rats given fenofibrate.
Conclusions: The PPARalpha agonist fenofibrate, and to a lesser extent the PPARaplha agonist Wyeth 14643,
maintained BMD and bone architecture at sham levels, while the PPARgamma agonist pioglitazone exaggerated
bone loss and negatively affected bone architecture, in ovariectomized rats.
Background
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated nuclear receptors, and exist as three dif-
ferent subtypes in mammals (PPARa,P P A R δ and
PPARg (with isoforms g1, g2a n dg3)) [1,2]. All PPARs
form heterodimers with the 9-cis-retinoic acid receptor
(RXR). PPARs are ubiquitously expressed, but with a tis-
sue specific distribution, and are involved in the regula-
tion in a broad specter of biological processes,
particularly in carbohydrate and lipid homeostasis [2-5].
Endogenous ligands for PPARs include eicosanoids, fatty
acids and fatty acid derivatives [3].
Because of their metabolic actions, PPARs (as yet pre-
ferentially PPARa and g) have become major drug tar-
gets [6]. Wyeth 14643 (pirinixic acid) is a potent PPARa
receptor activator [7], but not in clinical use due to
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class of fibrates which are mainly PPARa agonists, and
is currently used for treatment of hypercholesterolemia
and hypertriglyceridemia. Fibrates may also activate
PPARg and δ, but to a much lesser degree and this may
also vary between the different fibrates [4,9]. Thiazolidi-
nediones/glitazones are synthetic PPARg agonists used
for treatment of type 2 diabetes mellitus (T2DM)
[2,3,10].
All PPARs are expressed in both human and rodent
osteoblasts and osteoclasts, as reviewed by Giaginis et
al. [11], and a role for the PPARs in the regulation of
bone metabolism, has been proposed. Although the sig-
nificance of PPARa and its agonists in bone metabolism
remains poorly elucidated, we have demonstrated that
administration of the PPARa agonist fenofibrate,
increases femoral bone mineral density (BMD) and
reduces medullary area in intact female rats [12,13], sug-
gesting a positive impact on skeletal homeostasis.
Recently, bezafibrate and linoleic acid which are
PPARa/δ agonists [4], were shown to up regulate osteo-
blast differentiation and induce periosteal bone forma-
tion in intact male rats [9].
While the information on the role of PPARa and
PPARδ in bone is sparse, more is known about the sig-
nificance of PPARg. In vitro,P P A R g agonists promote
adipocyte differentiation preferentially over osteoblast
differentiation [14-18]. PPARg might act as a molecular
switch driving differentiation of mesenchymal stem cells
(MSC) into adipocytes, and PPARg insufficiency
enhances differentiation of osteoblast progenitors [19].
T h er o l eo fP P A R g activation in osteoclasts is less char-
acterized with several contradictory reports [20-23]. In
vivo studies revealed elevated bone loss in rodents trea-
ted with the PPARg agonists rosiglitazone [24-28] and
darglitazone [29]. We have previously shown that the
PPARg agonist pioglitazone reduces whole body BMD
and causes impairment of the mechanical strength in
normal female rats [12,13]. Glitazones also induce bone
loss in elderly women [30] and men [31] with T2DM.
Furthermore, an increased fracture risk was observed in
T2DM women treated with glitazones [32]. Even short-
term glitazone treatment decreased bone formation and
BMD in healthy, non-diabetic postmenopausal women
[33].
In order to better characterize the role of PPARa in
bone, we examined the long-term skeletal effects of the
PPARa agonists fenofibrate and Wyeth 14643 in ovar-
iectomized rats, and compared the effects to those of
the PPARg agonist pioglitazone. Bone effects were moni-
tored using DXA and μCT. Additionally, plasma levels
of osteocalcin and fragments of collagen type I, and the
adipokines leptin and adiponectin, were analyzed.
Methods
Materials
Fenofibrate was a gift from Professor Rolf Berge at the
University of Bergen, Norway, Wyeth 14643 was pur-
chased from ChemSyn Laboratories, USA, and pioglita-
zone was kindly provided by Eli Lilly, Norway.
Methylcellulose (M7140, Sigma-Aldrich, Norway) was
used as vehicle in the in vivo study.
Animals
The Animal Welfare Committee at St. Olav’sU n i v e r s i t y
Hospital in Trondheim approved the study. Ovariectomy
was used as a model-system for osteoporosis in rodents
[34-36].
Fifty-five female Sprague Dawley rats, 12 weeks of age,
(252 ± 16.4 g) were housed in wire-top cages with aspen
woodchip bedding (B&K Universal Ltd, UK). Room tem-
perature was 24 ± 1.0°C with a relative humidity of 40-
50% and a twelve-hour light/dark cycle. Rat and Mouse
Diet (B&K Universal Ltd) and tap water were provided
ad libitum. The animals were randomly assigned to five
groups of eleven rats. One group was sham-operated
and given vehicle (SHAM). The other four groups were
ovariectomized and given vehicle (OVX), fenofibrate
(90.0 mg/kg) (FENO OVX), Wyeth 14643 (90.0 mg/kg)
(WY OVX) or pioglitazone (35.0 mg/kg) (PIO OVX),
respectively, by daily intragastric gavage. All agents were
dissolved in methylcellulose. The doses of the different
agents were chosen according to results obtained in
other studies [37-39]. Administration of test substances
was initiated one week after surgery, and lasted for four
months. The rats were weighed at baseline and weekly
throughout the study, and femoral and whole body
DXA scans were performed in duplicates at baseline,
and after two and four months.
Animals were anesthetized with 2.0 ml/kg body weight
of a combination of fluanison (2.5 mg/ml), fentanyl (50
μg/ml), and midazolam (1.25 mg/ml), before surgery,
DXA scans, and prior to sacrifice.
Blood samples were collected by cardiac puncture dur-
ing final anaesthesia. After sacrifice, both femurs were
dissected, weighed, lengths measured, and stored at -80°
C or 4% formalin until analyzed. The livers were dis-
sected and weighed.
DXA measurements
Body weight (g), fat mass (g), lean mass (g), bone
mineral content (BMC) (g), as well as whole body and
femur BMD (g/cm
2), were measured by DXA in
anesthetized animals, using a Hologic QDR 4500A, and
small animal software. The coefficient of variation (CV)
was 2.4% for body weight, 2.2% for fat mass, 0.28% for
lean mass, 0.54% for whole body BMC, 3.0% for femur
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BMD. BMC and BMD are presented as % change from
baseline.
μCT measurements
The proximal femurs, including the femoral head and
the metaphysis of the dissected formalin-fixed femurs
were scanned in a SkyScan 1072 microtomograph (Sky-
S c a n ,A n t w e r p ,B e l g i u m ) ,w i t hav o x e l s i z eo f1 1 . 8 9μm.
Scans were processed, and three-dimensional morpho-
metric analyses of the femurs were done using free soft-
ware of the 3D-Calc Project (http://www.erasmusmc.nl/
47460/386156/Downloads). Femoral head and metaphy-
sis data sets were analyzed separately. Cortcial bone and
trabecular bone were separated using in-house devel-
oped software. For each cross-section in the 3D dataset,
a virtual mask of the total bone was created and used to
identify the bone marrow regions in the original image.
The marrow regions were expanded into a mask of the
total marrow cavity using a close operation. Bone inside
the total marrow cavity is considered trabecular bone,
the remainder is regarded as cortex. Cortical bone
volume (Ct.V, μm
3), cortical thickness (Ct.Th, μm), tra-
becular bone volume (BV, μm
3), total bone volume, the
region of interest adjacent to the endocortical boundary
including the trabecular bone as previously described
[40] (TV, μm
3), trabecular thickness (Tb.Th, μm), trabe-
cular bone volume fraction (BV/TV), connectivity den-
sity (CD, 1/mm
3) [41] and structure model index (SMI,
(0-3)) [42] were determined. SMI indicates whether the
trabeculae are more rod-like (SMI = 3) or more plate-
like (SMI = 0), and values between 0 and 3 represent
the volume ratio of rods and plates, analyzed as pre-
viously described [42].
Biomechanical testing
The right femurs were thawed in Ringers
® solution
before mechanical testing of the femoral neck and shaft
was performed. The shafts were fractured 18.7 mm from
the femoral condyles in three point cantilever bending as
previously described [43]. The proximal femur was fixed
in a clamp, the cam of the rotating wheel engaged the
femoral condyles, and a fulcrum positioned 18.7 mm
anteriorly from the condyles was the third point of force
application. All tests were done at a loading rate of 0.095
radians/second (5.43°/second). The load in the test appa-
ratus, a MTS 858 Mini Bionix
® Axial/Torsional Test Sys-
tem (MTS Systems Corporation, Minnesota, USA), was
measured with a MTS Test Star TM Sensor Cartridge
Force 250 N load cell and registered in MTS Test Star II
software. Ultimate bending moment (M) was calculated
a st h eu l t i m a t el o a db e f o r ef a i l u r em u l t i p l i e db yt h e
moment arm by which the load was applied (Newton
Meter, Nm). Energy absorption and stiffness were read
directly or calculated from the computer recordings as
previously described [43].
Osteocalcin, CTx, leptin and adiponectin analyses in rat
plasma
The amount of osteocalcin in plasma was determined by
a Rat-MID osteocalcin enzyme-linked immunosorbent
assay (ELISA) kit (Nordic Bioscience Diagnostics A/S,
Denmark), according to the manufacturer’sp r o t o c o l .
The detection limit was 50 ng/ml, and intra- and inter-
assay variations were 5.0% and 5.5%, respectively. Bone
resorption markers in plasma (CTx) were analyzed by a
RatLaps ELISA kit (Nordic Bioscience Diagnostics A/S)
according to the instructions from the manufacturer.
The detection limit was 3.0 ng/ml, and intra- and inter-
assay variations were 5.6% and 11%, respectively. Leptin
and adiponectin were analyzed in rat plasma by radio-
immunoassays (RIA) according to the manufacturer’s
protocol (Linco Research, USA). Detection limits were
3.0 pg/ml for leptin and 41 pg/ml for adiponectin. Intra-
and interassay variations for the RIAs were < 14% and <
4.0%, respectively.
Bone marrow cell preparation
Bone marrow cells were obtained from femurs and
tibiae from three intact female Sprague Dawley rats (251
± 4.5 g) by centrifugation as described by Dobson et al.
[44]. Briefly, tibiae and femurs were removed and all
soft tissue was removed. The proximal ends were cut
off, and the bones briefly centrifuged (1000 g, 10 s). The
bone marrow pellets from each animal were pooled and
resuspended in culture med i u ma n dp a s s e dt h r o u g ha
21-gauge needle to achieve a single cell suspension.
Mineralizing fibroblast-colony-forming unit cultures
assays
For in vitro studies: Dulbecco’s Modified Eagle Medium
(DMEM) was supplemented with penicillin/streptomycin
(10 U/ml), L-glutamine (0.1 mg/ml), sodium pyruvate
(1.0 mM), (all from Gibco BRL Invitrogen, Paisley, UK).
Mineralizing fibroblast-colony-forming unit (mCFU-f)
cultures assays were performed essentially as previously
described by Scutt et al. [45]. Nucleated bone marrow
cells from three female rats were seeded in DMEM/10%
fetal calf serum (FCS) (EuroClone, Devon, UK) with 10
nM dexamethasone (Sigma, Oslo, Norway), 50 μg/ml
ascorbic acid (Sigma) and 2.0 mM b-glycerophosphate,
in 6 well-plates (1.0 × 10
6 cells/well). Experiments were
performed with cells from three female rats in three
individual experiments, and with at least three parallel
wells for each concentration of the drugs. Cells were
treated with vehicle and different concentrations of
the PPARa agonist fenofibrate and the PPARg agonist
pioglitazone (0.01-10 μM ) .T h em e d i aw e r ec h a n g e d
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Cultures were terminated by washing with phosphate-
buffered saline (PBS) and fixed by adding cold 100%
ethanol. Wells were stained for alkaline phosphatase
(ALP) by addition of 0.5 mg/mL napthol AS-BI phos-
phate (Sigma) and 1.0 mg/mL fast red B (Sigma) in Tris
buffer (pH 7.5) for 30 minutes, washed with distilled
water, photographed with a digital camera, and
destained with 100% ethanol over night. Calcium-
positive colonies were stained with 1.0 mg/mL alizarin
red (Sigma) in distilled water adjusted to pH 5.5 with
NH3 for 30 minutes, washed with distilled water, photo-
graphed, and destained with 5% perchloric acid for
5 minutes. Collagen-positive colonies were stained with
1.0 mg/mL sirius red (Sigma) in statured picric acid for
18 hours, washed with distilled water and photographed.
Picture processing was performed in Adobe Photoshop
software (Adobe, San Jose, CA, USA) and quantification
of colonies was performed using the ImageQuant Soft-
ware (Amersham Biosciences, Piscataway, NJ, USA).
Statistical analyses
All measurements were performed in duplicates or
triplets. Data are expressed as means ± SD or means ±
SEM, as indicated in figures and tables. All data were
tested for normality with the Shapiro-Wilk normality
test. Normally distributed parameters were tested with
two-tailed unpaired Student’s t-test, or one-way
ANOVA with Bonferroni’s post test, while parameters
that were not normally distributed were tested with
Mann-Whitney’s two tailed test, or Kruskal Wallis test
with Dunn’s post test. Significance was assumed at
p-values lower than 0.05. Fat and lean mass are pre-
sented in % of body weight and whole body and femoral
BMD and BMC data are presented as % change from
baseline. Correlations between ultimate bending
moment in the femoral neck and shaft and whole body
and femoral BMD were analyzed with a two-way Spear-
man’s Rank correlation test.
Results
General observations and body composition
A total of seven rats died during the study, two rats in
the WY OVX group, two in the PIO OVX group, and
one rat in each of the other groups. There were no dif-
ferences in body weight, lean or fat mass between the
groups seven days after surgery, when administration of
test substances was initiated. The body weight increased
in all groups from baseline until the end of the study
(Figure 1A). There was no difference in body weight
between the four OVX groups during the study, but
they all had significantly higher body weight than the
SHAM group after two and four months (Figure 1A).
All OVX groups except WY OVX had significantly
higher % fat mass than the SHAM group after four
months (Figure 2B), while the PIO OVX group had
significantly higher % fat mass and lower % lean mass
than all other groups after both two and four months
(Figures 1B and 1C). The FENO OVX and the WY
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Figure 1 Body weight (A), fat mass in % of body weight (B)
and leans mass in % of body weight (C) at baseline, 2 and 4
months. Rats were either sham operated and given vehicle (SHAM)
or ovariectomized and given vehicle (OVX), Wyeth 14643 (WY OVX),
fenofibrate (FENO OVX) or pioglitazone (PIO OVX) respectively. Data
are presented as means ± SEM.
a, aa,aaa = p < 0.05, p < 0.01, p <
0.001 compared to the SHAM,
b,bb = p < 0.05, p < 0.01 compared
to the OVX.
c, cc,ccc = p < 0.05, p < 0.01, p < 0.001 compared to
FENO OVX.
dd,ddd = p < 0.01, p < 0.001 compared to WY OVX.
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Page 4 of 13OVX had similar lean mass as SHAM, while the OVX
controls had significantly lower lean mass than SHAM
after four months (Figure 1C).
The length and weight of the femurs did not differ
between the groups.
The liver weights (in % of total body weight) were
higher in the WY OVX group (4.34 ± 0.61%) and the
FENO OVX group (3.58 ± 0.58%), compared to the
other groups; vs. SHAM; 2.34 ± 0.28% (p < 0.001 and
p <0 . 0 0 1 ) ,v s .O V X ;2 . 1 9±0 . 0 9 %( p <0 . 0 0 1a n dp <
0.001), and vs. PIO OVX; 2.18 ± 0.50%, (p <0 . 0 0 1a n d
p < 0.001). We did not detect any liver pathology by
gross visual inspection, however livers were not further
examined, as this was not within the scope of this
study.
In conclusion, all the ovariectomized groups had
increased body weight compared to SHAM, while the
PIO OVX had a significantly higher fat mass than all
the other groups (Figure 1).
Whole body and femoral BMC and BMD
There were no differences in whole body or femoral BMC
or BMD between the groups seven days after surgery (at
the beginning of administration). There was an increase in
% change in whole body BMC from baseline in all groups
throughout the study (Figure 2A). All ovariectomized
groups had a significantly higher whole body BMC than
the SHAM group after two and four months, but there
was no significant difference in whole body BMC between
the ovariectomized groups at any time (Figure 2A).
Whole body BMD increased in all groups, except for
the PIO OVX group, where a decline from baseline was
observed (Figure 2B). The WY OVX group had a signifi-
cantly higher increase in whole body BMD than the
OVX group, after four months.
After four months, an increase in femoral BMC was
observed in all groups (Figure 2C). However, the change
in femoral BMC for the OVX and PIO OVX groups were
significantly lower than the SHAM group (Figure 2C),
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Figure 2 Whole body BMC (A), whole body BMD (B), femoral BMC (C) and femoral BMD (D) in % change from baseline after 2 and 4
months. Rats were either sham operated and given vehicle (SHAM) or ovariectomized and given vehicle (OVX), Wyeth 14643 (WY OVX),
fenofibrate (FENO OVX) or pioglitazone (PIO OVX) respectively. Data are presented as means ± SEM.
a,aa,aaa = p < 0.05, p < 0.01, p < 0.001
compared to SHAM.
b,bbb = p < 0.05, p < 0.001 compared to OVX.
c,cc,ccc = p < 0.05, p < 0.01, p < 0.001 compared to FENO OVX.
dd,ddd = p <
0.01, p < 0.001 compared to WY OVX.
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Page 5 of 13while maintained at SHAM levels in FENO OVX and
WY OVX, and significantly higher in the FENO OVX
group compared to OVX controls after four months
(FENO OVX; +21.3 ± 4.2% vs. OVX; +10.0 ± 1.6%, p =
0.03) (Figure 2C).
The gain in femoral BMD from baseline was similar in
the SHAM and FENO OVX groups, while no gain was
observed in the OVX and WY OVX groups after four
months. In the PIO OVX there was a decline in femoral
BMD from baseline (Figure 2D). The increase in femoral
BMD was significantly higher in the SHAM and the
FENO OVX groups after four months compared to the
OVX group (SHAM; +3.3 ± 0.8% vs. OVX; 0.0 ± 1.2%, p
=0 . 0 3a n dF E N OO V X ;+ 8 . 3±4 . 2 %v s .O V X ;0 . 0±
1.2%, p = 0.03) (Figure 2D).
In summary, ovariectomized rats given fenofibrate and
Wyeth maintained whole body and femur BMD at sham
or ovariectomized controls levels, while the PIO OVX
group had a pronounced decrease in BMD compared to
all the other groups.
Bone architecture
μCT analyses revealed significantly higher TV and SMI,
and lower Ct.V, Ct.Th and BV/TV ratio in both the
femoral heads and metaphyses in the OVX compared to
the SHAM group (Tables 1 and 2). Furthermore, Tb.Th
in the femoral head, and BV in the femoral metaphysis
were significantly reduced in the OVX group compared
to the SHAM group (Tables 1 and 2).
The FENO OVX group maintained TV and Tb.Th in
the femoral head and the Ct.V, BV and TV in the meta-
physis at SHAM levels, in contrast to the OVX control
group (Table 1 and 2). However, Ct.Th and BV/TV
ratio in both the femoral head and metaphysis were sig-
nificantly lower in the FENO OVX group compared to
the SHAM group (Tables 1 and 2).
The PIO OVX group had significantly lower Ct.V, Ct.
Th, and BV/TV in both the femoral head and the meta-
physis, and also the highest EV, compared to all other
groups (Tables 1 and 2). In addition, the PIO OVX
group had significantly lower BV in the metaphysis than
the SHAM group, and significantly reduced Tb.Th in
the femoral head compared to the other groups (Tables
1 and 2).
T h e r ew a sn od i f f e r e n c ei nC Db e t w e e nt h eg r o u p s ,
except in the WY OVX group, which showed signifi-
cantly higher CD in the femoral metaphysis, compared
to the FENO OVX and OVX groups (Table 2). All the
ovariectomized groups exhibited significantly higher
SMI than the SHAM group, both in the femoral head
and metaphysis, except for WY OVX in the femoral
head (Tables 1 and 2).
In conclusion, ovariectomized rats given fenofibrate,
and to some extent rats given Wyeth 14643, partly
maintained bone architectural structures at sham levels
in the femur, while ovariectomized rats given pioglita-
zone had further deterioration of femoral bone
architecture.
Biomechanical testing
The FENO OVX and WY OVX groups maintained the
ultimate bending moment and energy absorption at
sham levels in the femoral neck (Table 3). The OVX
controls had significantly lower bending moment and
energy absorption in the femoral neck compared to
SHAM, while the PIO OVX group had significantly
lower bending moment and energy absorption than all
the other groups except OVX controls in the femoral
neck, and all the other groups for the femoral neck
(Table 3). There was no significant difference between
the groups regarding stiffness, neither in the femoral
neck nor shaft (Table 3).
Plasma osteocalcin, CTx, leptin and adiponectin
Plasma osteocalcin levels were significantly higher in the
OVX (463 ± 36 ng/ml, p = 0.0291) and FENO OVX
groups (438 ±19 ng/ml, p = 0.0119) compared to the
SHAM group (367 ± 17.5 ng/ml) (Figure 3A). The WY
OVX group (365 ± 84 ng/ml) had significantly lower
osteocalcin levels than the OVX group (p = 0.05), but
did not differ from the SHAM group (Figure 3A). The
PIO OVX rats had significantly lower plasma osteocalcin
than all other groups (256 ± 29 ng/ml, p = 0.0033 vs.
SHAM, p =0 . 0 1 1 4v s .O V X ,p < 0.0001 vs. FENO OVX
and p < 0.0001 vs. WY OVX) (Figure 3A).
Plasma CTx levels were significantly lower in the PIO
OVX group (12.3 ± 1.8 ng/ml, p = 0.0006) compared to
the OVX group (21.7 ± 4.4 ng/ml) (Figure 3B). There
were no significant differences in CTx levels between any
of the other groups (SHAM 25.9 ± 2.5 ng/ml, FENO
OVX; 18.4 ± 2.9 ng/ml, WY OVX; 22.8 ± 6.8 ng/ml)
(Figure 3B).
Plasma leptin levels were significantly higher in the
OVX (6.0 ± 0.3 ng/ml, p = 0.0006) and PIO OVX groups
(5.9 ± 1.4 ng/ml, p = 0.0008) compared to the SHAM
group (2.6 ± 0.3 ng/ml) (Figure 3C). There was no differ-
ence in the plasma leptin levels between the FENO
OVX (3.5 ± 1.7 ng/ml), WY OVX(2.6 ± 1.7 ng/ml) and
SHAM groups, but the FENO OVX and WY OVX
groups had significantly lower plasma leptin than the
OVX group (p = 0.0106 and p = 0.0022, respectively)
(Figure 3C).
Plasma adiponectin levels were significantly increased
in all ovariectomized groups (OVX; 10.4 ± 0.6 μg/ml,
p = 0.0081, FENO OVX; 9.1 ± 0.6 μg/ml, p = 0.0338,
WY OVX; 9.8 ± 2.0 μg/ml, p = 0.0077, PIO OVX; 20.4
±1 . 1μg/ml, p< 0.0001) compared to the SHAM group
(7.2 ± 0.6 μg/ml) (Figure 3D). The PIO OVX group had
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Page 6 of 13also significantly higher plasma adiponectin levels com-
pared to the OVX, FENO OVX and WY OVX groups
(p < 0.0001 for all) (Figure 3D).
Effect of fenofibrate and pioglitazone on differentiation
of rat bone marrow cells
The PPARa agonist fenofibrate (1.0 and 10 μM) signifi-
cantly increased the number of ALP (+20-55%), calcium
(+37-70%) and collagen (+18-26%)-positive colonies in
rat bone marrow cells examined with the mCFU-f assay
(Figure 4). On the other hand, the PPARg agonist piogli-
tazone (0.1, 1.0 and 10 μM) significantly reduced the
number of ALP (-57-90%), calcium (-45-85%) and col-
lagen (-30-77%)-positive colonies (Figure 4). Also, piogli-
tazone led to adipocyte forming colonies, with clearly
visual formation of lipid droplets (data not shown).
Discussion
Our study provides the first evidence that administration
of the PPARa agonists fenofibrate and Wyeth 14643 to
a certain level can maintain bone quality at sham levels
in an ovariectomized rat model. Furthermore, this study
differentiates the PPARa agonists from the PPARg ago-
nists regarding skeletal effects, since the PPARg agonist
pioglitazone exerts the opposite effect by further boost-
ing ovariectomy-induced bone loss in rats.
Ovariectomized control rats had significantly lower
gain in femoral BMC and BMD associated with reduced
biomechanical strength parameters compared to sham-
operated controls. The relatively young age of the rats
may explain why the differences found between the
SHAM and OVX controls were less pronounced than
expected. According to Kahrode et al, 2008 [46], rats
from 2-15 months are applied in the rat OVX model,
and while use of older animals is attractive due to steady
bone turnover rate, the use of young adult rats can also
provide consistent, reproducible and interpretable
results. Ovariectomy of skeletally immature rats results
in achievement of a lower peak bone mass (total bone
mass present at the end of the skeletal maturation,
which for rats are considered to occur between 47-61
weeks of age [47]).
In our study, fenofibrate had a partly preventive effect
on bone in this rat model of osteoporosis, as femoral
and whole body BMC and BMD were maintained at the
same levels as for sham-operated rats, and this group
also exhibited significantly higher femoral BMC and
BMD than ovariectomized controls. Fenofibrate also
prevented deterioration of the bone architecture to a
certain level, as reflected in maintenance of trabecular
BV, trabecular thickness Tb.Th, and TV. We have pre-
viously shown that fenofibrate increased femoral BMD
Table 1 Mean values ± SD of bone architecture parameters in the femoral head, determined by means of μCT
scanning analyses in rats after 4 months of treatment
FEMORAL HEAD SHAM (sham-
operated controls)
(N = 10)
OVX
(ovariectomized
controls)
(N = 10)
WY OVX
(ovariectomized, given
Wyeth 14643)
(N = 9)
FENO OVX
(ovariectomized,
given fenofibrate)
(N = 10)
PIO OVX (ovariectomized,
given pioglitazone)
(N = 9)
CORTICAL VOLUME
(Ct.V) (μm
3)
31.98 ± 2.449 28.26 ± 1.491
aa 28.59 ± 1.825
aa 27.71 ± 2.443
aaa 23.36 ± 1.578
aaa, bbb, ccc, ddd
CORTICAL
THICKNESS
(Ct.Th) (μm)
449.4 ± 18.80 422.3 ± 21.21
a 419.5 ± 19.64
aa 426.5 ± 18.48
a 372.7 ± 15.69
aaa, bbb, ccc, ddd
TRABECULAR BONE
VOLUME (BV) (μm
3)
10.94 ± 1.365 10.69 ± 1.291 11.03 ± 1.176 10.25 ± 1.284 10.17 ± 1.468
TOTAL
VOLUME (TV) (μm
3)
20.12 ± 2.062 23.70 ± 2.926
a 23.70 ± 2.926
aa 21.62 ± 1.737 26.52 ± 1.924
aaa, b, ccc, d
TRABECULAR
THICKNESS (Tb.Th)
(μm)
155.2 ± 6.893 147.2 ± 3.445
a 146.2 ± 4.298
aa 150.6 ± 4.886 138.9 ± 6.828
aaa, b, ccc, d
CONNECTIVITY
DENSITY (CD) (1/
mm
3)
44.42 ± 9.160 46.34 ± 7.634 60.49 ± 20.60 47.26 ± 5.699 46.09 ± 5.317
STRUCTURE MODEL
INDEX (SMI) (0.0-3.0)
0.6509 ± 0.2211 0.9811 ± 0.1391
a 0.8556 ± 0.1588 0.9610 ± 0.1824
aa 1.179 ± 0.4074
aaa,d
TRABECULAR BONE
VOLUME FRACTION
(BV/TV)
0.5436 ± 0.04273 0.4511 ± 0.02421
aaa 0.4700 ± 0.07018 0.4720 ± 0.03425
aa 0.3833 ± 0.05050
aaa, b, cc, d
a, aa, aaa = p < 0.05, p < 0.01, p < 0.001 when compared to SHAM group.
b, bb, bbb = p < 0.05, p < 0.01, p < 0.001 when compared to OVX group.
c, cc, ccc = p < 0.05, p < 0.01, p < 0.001 when compared to FENO OVX group.
d, dd, ddd = p < 0.05, p < 0.01, p < 0.001 when compared to WY OVX group.
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Page 7 of 13Table 2 Mean malues ± SD of bone architecture parameters in the femoral metaphysis, determined by means of μCT
scanning analyses in rats after 4 months of treatment
FEMORAL METAPHYSIS SHAM
(sham-operated
controls)
(N = 10)
OVX
(ovariectomized
controls)
(N = 10)
WY OVX
(ovariectomized,
given Wyeth 14643)
(N = 9)
FENO OVX
(ovariectomized,
given fenofibrate)
(N = 10)
PIO OVX
(ovariectomized, given
pioglitazone)
(N = 9)
CORTICAL VOLUME
(Ct.V) (μm
3)
28.77 ± 1.773 27.13 ± 1.551
a 28.14 ± 1.222 28.71 ± 1.795 23.37 ± 1.225
aaa, bbb, ccc, ddd
CORTICAL THICKNESS
(Ct.Th) (μm)
735.5 ± 22.90 694.4 ± 41.84
a 700.6 ± 21.83
aa 709.9 ± 28.52
a 594.7 ± 39.58
aaa, bb, cc, ddd
TRABECULAR BONE
VOLUME (BV) (μm
3)
6.554 ± 0.8317 5.147 ± 0.5373
aa 5.697 ± 0.6074
a 5.615 ± 1.410 4.996 ± 1.048
aa
TOTAL
VOLUME (TV) (μm
3)
21.85 ± 1.640 25.23 ± 1.734
a 23.65 ± 1.828 23.76 ± 2.448 28.58 ± 2.513
aaa, b, ccc, ddd
TRABECULAR
THICKNESS (Tb.Th) (μm)
148.3 ± 5.638 146.7 ± 6.034 144.1 ± 6.402
c 154.8 ± 11.59 141.5 ± 6.146
aa, cc
CONNECTIVITY
DENSITY (CD) (1/mm
3)
14.20 ± 5.740 10.91 ± 2.118 17.91 ± 5.004
bb,c 12.01 ± 4.295 11.56 ± 2.533
dd
STRUCTURE MODEL
INDEX (SMI) (0.0-3.0)
0.6682 ± 0.2296 1.596 ± 0.2397
aaa 1.394 ± 0.1283
aaa, b 1.518 ± 0.2138
aaa 1.742 ± 0.2773
aaa, dd
TRABECULAR BONE
VOLUME FRACTION
(BV/TV)
0.2991 ± 0.03208 0.2056 ± 0.02008
aaa 0.2389 ± 0.02892
aaa, b 0.2340 ± 0.04048
aaa 0.1744 ± 0.02128
aaa, bb, cc, ddd
a, aa, aaa = p < 0.05, p < 0.01. p < 0.001 when compared to SHAM group.
b, bb, bbb = p < 0.05, p < 0.01, p < 0.001 when compared to OVX group.
c, cc, ccc = p < 0.05, p < 0.01, p < 0.001 when compared to FENO OVX group.
d, dd, ddd = p < 0.05, p < 0.01, p < 0.001 when compared to WY OVX group.
Table 3 Mechanical properties of the femoral neck and shaft in mean values ± SD after 4 months of treatment
SHAM (sham-
operated controls)
(N = 10)
OVX
(ovariectomized
controls)
(N = 10)
WY OVX (ovariectomized,
given Wyeth 14643)
(N = 9)
FENO OVX
(ovariectomized, given
fenofibrate)
(N = 10)
PIO OVX (ovariectomized,
given pioglitazone)
(N = 9)
ULTIMATE
BENDING
MOMENT
(Nm)
Femoral
neck
Femoral
shaft
63.0 ± 8.9
81.7 ± 6.3
52.1 ± 8.9
a
76.8 ± 7.6
62.0 ± 12
79.4 ± 3.7
56.5 ± 9.8
75.0 ± 4.9
47.6 ± 8.2
a,c,dd
65.4 ± 7.2
aaa,bb,c,ddd
ENERGY
ABSORPTION
(J × 10
-2)
Femoral
neck
Femoral
shaft
13.5 ± 2.7
15.3 ± 2.3
9.94 ± 2.6
a
13.3 ± 2.8
13.8 ± 3.7
b
13.9 ± 1.4
12.0 ± 3.7
14.3 ± 2.0
8.60 ± 2.2
aaa,c,dd
10.0 ± 3.2
aa,b, cc,d
ULTIMATE
BENDING
STIFFNESS
(Nm/° × 10
-
2)
Femoral
neck
Femoral
shaft
370 ± 58
574 ± 61
317 ± 53
582 ± 58
359 ± 81
586 ± 66
344 ± 49
550 ± 35
339 ± 83
540 ± 81
a, aa, aaa = p < 0.05, p < 0.01, p < 0.001 when compared to SHAM group.
b, bb, bbb = p < 0.05, p < 0.01, p < 0.001 when compared to OVX group.
c, cc, ccc = p < 0.05, p < 0.01, p < 0.001 when compared to FENO OVX group.
d, dd, ddd = p < 0.05, p < 0.01, p < 0.001 when compared to WY OVX group.
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Page 8 of 13and reduced bone medullary area in intact female rats
[12,13] suggesting an inhibition of endosteal bone
resorption. Chan et al. found that fibrates directly inhi-
bit human osteoclast activity and function [22], and
Okamoto et al. demonstrated that fenofibrate suppresses
osteoclast differentiation by inhibiting NFB-signaling
[48]. We have, however, not been able to confirm a
direct effect of fenofibrate on human osteoclasts [13].
This is consistent with the findings of Still et al., who
showed that administration of bezafibrate to rats caused
no change in either the number of osteoclasts or the
serum levels of resorption markers [9].
In contrast to the ovariectomized control group, rats
given fenofibrate and Wyeth 14643 had similar bending
moment and energy absorption as the sham group at
the femoral neck, indicating maintained mechanical
strength in spite of the ovariectomy.
Furthermore, administration of fenofibrate and Wyeth
14643 resulted in maintenance of femoral BMC at the
same level as the sham control group.
We have previously shown that fenofibrate stimulates
osteoprotegerin (OPG) release from the mouse preos-
teoblast cell line MC3T3-E1 [13], and it has also been
found to enhance plasma OPG in humans [49]. These
findings suggest an antiresorptive effect of fenofibrate.
In a previous study, we demonstrated that fenofibrate
elevated plasma osteocalcin levels in intact female rats
[13]. In the present study, however, the plasma osteocal-
cin levels were similar in the ovariectomized group and
the fenofibrate group, and both groups had elevated
osteocalcin levels compared to the sham-operated
group. It is therefore difficult to differentiate if the ele-
vated level of plasma osteocalcin level in the fenofibrate
group is due to increased bone formation or increased
bone turnover associated with ovariectomy.
We and others have previously shown that activation
of PPARa increases osteoblast gene expression of differ-
entiation markers [13], increases ALP activity, induces
osteoblastic maturation and matrix calcification [50] in
MC3T3-E1 cells. In the present study we found that
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Figure 3 Osteocalcin (A), CTx (B), leptin (C) and adiponectin (D) in plasma. Rats were either sham operated and given vehicle (SHAM) or
ovariectomized and given vehicle (OVX), Wyeth 14643 (WY OVX), fenofibrate (FENO OVX) or pioglitazone (PIO OVX) respectively. Data are
presented as means ± SD.
a,aa,aaa = p < 0.05, p < 0.01, p < 0.001 compared SHAM.
b,bb, bbb = p < 0.05, p < 0.01, p < 0.001 compared to OVX.
c,ccc
= p < 0.05, p < 0.001 compared to FENO OVX group.
d,ddd = p < 0.05, p < 0.001 compared to WY OVX.
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Page 9 of 13fenofibrate significantly enhanced the number of ALP-,
calcium- and collagen-positive colonies in bone marrow
cells from rats.
Still et al. showed that bezafibrate and linoleic acid
increased BMD and periosteal bone formation in male
rats [9]. Since the most pronounced effect was found for
linoleic acid, which preferentially is a PPARδ agonist,
they concluded that the effects were mediated through
PPARδ activation. Wyeth 14643 and fenofibrate possess
high and equal affinity to PPARa [51], and we demon-
strate that administration of these PPARa agonists to
some level maintain bone mass and biomechanical at
sham levels.
The PIO OVX group exhibited enhanced bone loss
and impaired bone architecture, reflected in a significant
decrease in cortical volume and thickness in both
femoral head and shaft, and an elevated total volume. In
accordance with these findings, we also found reduced
mechanical strength in this group. These results are in
agreement with several earlier studies, all showing
reduced bone formation and/or a decrease in bone
mass, in rodents treated with glitazones, mainly rosigli-
tazone [24-29]. Similar findings were recently demon-
strated in humans [30-33,52,53]. Pioglitazone is still
used for treatment of diabetes mellitus 2, while rosiglita-
zone has been withdrawn due to adverse effects [54].
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Figure 4 Effects of fenofibrate and pioglitazone on osteoblast differentiation. Rat primary bone marrow cells were treated with increasing
doses of PPAR agonists for 21 days and stained sequentially for ALP (A), calcium (B) and collagen (C).
a = p < 0.05 compared with vehicle
treated cells.
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Page 10 of 13We show that pioglitazone causes negative skeletal
effects similar to those seen for rosiglitazone. Plasma
levels of osteocalcin were significantly reduced in the
PIO OVX group compared to all the other groups, sug-
gesting that the negative effect of PPARg agonists on the
skeleton is caused by inhibition of bone formation,
rather than elevated bone resorption. This is supported
by the fact that plasma CTx was significantly lower in
the rats receiving pioglitazone. Pioglitazone also reduced
the number of ALP-, calcium- and collagen -positive
colonies in vitro in bone marrow cells from rats. This is
in accordance with several other studies, showing that
pioglitazone [55] and the PPARg agonist BRL-49653
[56] stimulate adipogenesis, inhibit osteogenesis and
reduce ALP activity in mesenchymal cells from mouse
and rat bone marrow, respectively. We have previously
studied the effect of pioglitazone on human osteoclast
differentiation and activity [13], but could not detect
any effect with the doses used in our study (0.1-10 μM).
Studies regarding the effects of PPARg agonists on
osteoclasts are contradictory; some studies report an
inhibition of osteoclast differentiation and activity
[20,21,57], while others demonstrate a pro-osteoclasto-
genic effect of PPARg [22,58]. Since we could not
demonstrate a direct effect of either fenofibrate or pio-
glitazone on osteoclasts [13], we speculate whether the
observed skeletal effects of PPAR agonists mainly are
mediated through the regulation of mesenchymal cells
within the bone marrow.
The doses of rosiglitazone used in previous rodent
studies were 3.0-25 mg/kg/day, whereas we used a
higher daily dose of pioglitazone (35 mg/kg). Rosiglita-
zone is a more potent PPARg agonist than pioglitazone
[4], and several studies have estimated comparable gly-
cemic effects of rosiglitazone 2-8 mg with pioglitazone
15-45 mg, respectively [59-61].
Most studies of glitazones treatment in rodents
[24-29], also report enhanced bone marrow adiposity,
supporting evidence from in vitro studies in which
PPARg activation in bone cells was found to promote
adipogenesis at the expense of osteoblastogenesis
[14-16,18,62]. We did not measure the fat content in
bone marrow; the PIO OVX group, however, displayed
significantly higher body fat mass and lower % lean
mass than all the other groups, showing that PPARg
activation stimulates adipogenesis in general.
The FENO OVX group maintained % lean mass at
sham levels in contrast to the ovariectomized controls,
which is in accordance with our previous study where
fenofibrate increased lean mass in intact female rats
[13].
PPARa activation is found to induce hepatomegaly in
rodents [8] and in accordance with this we found
increased liver weights in the FENO and WY groups.
This was not examined any further, as this was beyond
the scope of this study.
The skeletal effects of PPAR agonists may also be
indirect, for instance through regulation of adipokine
production in adipose tissue. There is a connection
between the amount of body fat and bone mass as
recently reviewed by several authors [63-65]. Adipose
tissue produces several hormones assumed to be
involved in the regulation of bone metabolism, such as
adiponectin [66,67] and leptin [68,69]. However, there
are conflicting results concerning the skeletal effects of
adipokines [63-65].
In our study we found significant differences in
plasma leptin and adiponectin levels between the
groups, especially the PIO OVX group exhibited higher
levels than the others. In humans, circulating leptin con-
centrations correlate with body mass index (BMI) and
the total amount of body fat [70,71]. We found that the
WY OVX and the FENO OVX groups had similar
plasma leptin levels as SHAM, despite a significantly
higher body weight and fat mass. Adiponectin is known
to stimulate insulin sensitivity, and usually correlates
negatively with increased fat mass [72-74]. In spite of
the large enhancement in fat mass, the PIO OVX group
exhibited the highest level of plasma adiponectin among
the groups. This is in accordance with previous studies
demonstrating that glitazones increase circulating adipo-
nectin levels in humans as well as rodents [75-77]. It is
difficult to elaborate whether these differences explain
the various skeletal effects of PPARa and PPARg
agonists.
Conclusion
We present evidence for a positive effect of PPARa ago-
nists on bone. Fenofibrate and Wyeth 14643 maintained
to a certain level bone mass, some parameters of
femoral bone architecture and mechanical strength in
the femoral shaft at sham levels, in spite of ovariectomy.
We also confirm results from previous studies showing
major negative skeletal effects of PPARg agonists.
Fenofibrate is currently used to treat hyperlipidemia,
and our results indicate that fenofibrate could be benefi-
cial for the skeleton for patients on treatment.
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